Antiatherosclerotic effect of alacepril, an angiotensin-converting enzyme inhibitor, in monkeys fed a high-cholesterol diet

Hypertension Research - Clinical and Experimental

Volumn 22, Issue 1, 1999, Pages 49-54

  Miyazaki, Mizuo ^a   Takai, Shinji ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

ACE inhibitor; Alacepril; Atherosclerosis; Monkey; Vascular ACE

Indexed keywords

ALACEPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG MEGADOSE; ENZYME ACTIVITY; FEMALE; MALE; MEAN ARTERIAL PRESSURE; MONKEY; NONHUMAN; ORAL DRUG ADMINISTRATION; THORACIC AORTA;

EID: 0032961290     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.22.49     Document Type: Article

References (30)

1. Spence JD, Pesout AB, Melmon KL: Effects of anti-hypertensive drugs on blood velocity in rhesus monkeys. Stroke 1477; 8: 589-594.
2. Blumlein SL, Sievers R, Kidd P, Parmley WW: Mechanism of protection from atherosclerosis by verapamil in the cholesterol-fed rabbit. Am J Cardiol 1984; 54: 884-889.
3. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ: Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 1993; 91: 2268-2274.
4. Unger T, Badoer E, Ganten D, Lang RE, Rettig, R: Brain angiotensin: pathways and pharmacology. Circulation 1988; 77 (Suppl 1): 140-155.
5. Lindpaintner K, Jin M, Wilhelm M, Toth M, Ganten D: Aspects of molecular biology and biochemistry of the cardiac renin-angiotensin system. Br J Clin Pharmacol 1989; 27 (Suppl 2): S159-S165.
6. Egleme C, Cressier F, Wood JM: Local formation of angiotensin II in the rat aorta: effect of endothelium. Br J Pharmacol 1990; 100: 237-240.
7. Chobanian AV, Haudenschild CC, Nickerson C, Drago R: Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990; 15: 327-331.
8. Aberg G, Ferrer P: Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol 1990; 15 (Suppl 5): S65-S72.
9. Mitani H, Bandoh T, Kimura M, Totsuka T, Hayashi S: Increased activity of vascular ACE related to atherosclerotic lesions in hyperlipidemic rabbits. Am J Physiol 1996; 271: H1065-H1071.
10. Miyazaki M, Sakonjo H, Takai S, Shiota N: Antiatherosclerotic action of ACE inhibitors. J Hypertens 1996; 14 (Suppl 1): S138.
11. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC: Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20: 470-475.
12. Burstein M, Scholnick HR, Morfin R: Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res 1970; 11:583-595.
13. Chobanian AV, Hope S, Brecher P: Dissociation between the antiatherosclerotic effect of trandolapril and suppression of serum and aortic angiotensin-converting enzyme activity in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1995; 25: 1306-1310.
14. Heinecke JW: Free radical modification of low-density lipoprotein: mechanisms and biological consequences. Free Radic Biol Med 1987; 3: 65-73.
15. Ujhelyi MR, Ferguson RK, Vlasses PH: Angiotensin-converting enzyme inhibitors: mechanistic controversies. Pharmacotherapy 1989; 9: 351-362.
16. Keidar S, Kaplan M, Shapira C, Brook JG, Aviram M: Low density lipoprotein isolated from patients with essential hypertension exhibits increased propensity for oxidation and enhanced uptake by macrophages: a possible role for angiotensin II. Atherosclerosis 1994; 107: 71-84.
17. Kita T, Nagano Y, Yokode M, et al: Probucol prevents the progression of atheroselerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA 1987; 84: 5928-5931.
18. Mao SJ, Yates MT, Rechtin AE, Jackson RL, Van Sickle WA: Antioxidant activity of probucol and its analogues in hypercholesterolemic Watanabe rabbits. J Med Chem 1991; 34: 298-302.
19. Zhang SH, Reddick RL, Avdievich E, et al: Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice. J Clin Invest 1997; 99: 2858-2866.
20. Schuh JR, Blehm DJ, Frierdich GE, McMahon EG, Blaine EH: Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits. J Clin Invest 1993; 91: 1453-1458.
21. Naftilan AJ, Gilliland GK, Eldridge CS, Kraft AS: Induction of the proto-oncogene c-jun by angiotensin II. Mol Cell Biol 1990; 10: 5536-5540.
22. Gibbons GH, Pratt RE, Dzau VJ: Vascular smooth muscle cell hypertrophy vs. hyperplasia: autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest 1992; 90: 456-461.
23. Sugano M, Makino N, Yanaga T: The effects of renin-angiotensin system inhibition on aortic cholesterol content in cholesterol-fed rabbits. Atherosclerosis 1996; 127: 123-129.
24. Takai S, Shiota N, Kobayashi S, Matsumura E, Miyazaki M: Induction of chymase that forms angiotensin II in the monkey atherosclerotic aorta. FEBS Lett 1997; 412: 86-90.
25. Takai S, Shiota N, Sakaguchi M, Muraguchi H, Matsumura E, Miyazaki M: Characterization of chymase from human vascular tissues. Clin Chim Acta 1997; 265: 13-20.
26. Kaartinen M, Penttila A, Kovanen PT: Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation 1994; 90: 1669-1678.
27. Fournie Zaluski MC, Soroca Lucas E, Waksman G, Llorens C, Schwartz JC, Roques BP: Differential recognition of "enkephalinase" and angiotensin-converting enzyme by new carboxyalkyl inhibitors. Life Sci 1982; 31: 2947-2954.
28. Strittmatter SM, Thiele EA, Kapiloff MS, Snyder SH: A rat brain isozyme of angiotensin-converting enzyme: unique specificity for amidated peptide substrates. J Biol Chem 1985; 260: 9825-9832.
29. Johnson AR, Schulz WW, Noguiera LA, Erdös EG: Kinins and angiotensins: angiotensin I converting enzyme (kininase II) in endothelial cells cultured from human pulmonary arteries and veins. Clin Exp Hypertens 1980; 2: 659-674.
30. Linz W, Wiemer G, Schölkens BA: Contribution of bradykinin to the cardiovascular effects of ramipril. J Cardiovasc Pharmacol 1993; 22 (Suppl 9): S1-S8.